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Abstract 
Objectives: To evaluate whether elderly patients on 
amiodarone were having their thyroid function status monitored 
as recommended in the literature and to identify the frequency 
and type of thyroid function test abnormalities noted. 
Methods: Patients on amiodarone were identified by 
examining the prescription charts and medical files of 
consecutive admissions into Zammit Clapp Hospital (ZCH) and 
residents at St Vincent de Paul Residence (SVPR). Data was 
obtained on whether thyroid function tests had been checked 
at the start of the medication and every six months; the results 
of such tests carried out over the previous year; the clinical 
indication to prescribe the medication; and the course of action 
followed when results were abnormal. 
Results: 1334 prescription charts were examined. 69 
patients (5.2%) were on amiodarone. The most common clinical 
indication for the medication was atrial fibrillation (68.1%). As 
regards thyroid status, 39.1% of subjects had blood tests checked 
at the start of the medication but only 2.9% every 6 months. 
Although 75.4% had had their thyroid status checked over the 
previous year, 8.7% never had any thyroid function tests carried 
out whilst they were on the medication. In all 27.5% of subjects 
had thyroid gland dysfunction of which 13% had subclinical 
hypothyroidism, 11.6% clinical hypothyroidism and 2.9% clinical 
hyperthyroidism. All patients with abnormal results had been 
kept on amiodarone even when the arrhythmia had abated. 
Conclusions: Thyroid dysfunction is a common side effect 
of amiodarone medication. The regular measurement of thyroid 
function tests, as recommended, should be adhered to in a 
stricter manner. 
Introduction 
Amiodarone is classified as a Class III anti-arrhythmic 
drug which can be effective in the management of both 
supraventricular and ventricular tachyarrhythmias, including 
atrial fibrillation and flutter.¹ Each molecule of amiodarone 
contains two atoms of iodine and a normal maintenance 
dose of this medication will lead to a significant increase in a 
patient’s daily iodine intake.² The list of potential side effects 
with amiodarone therefore includes thyroid gland dysfunction¹ 
which may require specific treatment. 
Both hypothyroidism and hyperthyroidism have been 
described as complications of amiodarone medication.³ The 
overall incidence of amiodarone-induced thyroid dysfunction 
has been reported to range from 2 to 24%.4   Such a wide incidence 
range has mainly been attributed to different diagnostic criteria 
being used by various authors5 as some studies only included 
patients with clinical or overt thyroid dysfunction [defined as 
abnormal levels of both Thyroid Stimulating Hormone (TSH) 
and Thyroxine/Tri-iodothyronine (T4/T3) with clinical features] 
whilst other studies also included subjects with subclinical 
findings [defined as abnormal TSH levels only with normal 
T4/T3 levels and no clinical features].3,6 For example, Fuks et 
al5 , who found a particular high incidence of abnormalities of 
thyroid function tests (33.9%) in their sample of 56 patients 
on amiodarone (mean age 58.0 years), diagnosed subclinical 
thyroid dysfunction in 21.4% and clinical thyroid dysfunction 
in 12.5%. 
In the elderly, reaching a diagnosis of thyroid dysfunction can 
be rendered more difficult by a lack of classical clinical features 
even when patients have both TSH and T4/T3 abnormalities. 
Over thirty years ago, Bahemuka and Hodkinson7 had noted 
that a non-specific clinical picture was particularly common in 
the elderly with laboratory confirmed hypothyroidism since less 
than a third of cases showed typical symptoms and signs. More 
recently, Findlay and Seymour8 described a case of amiodarone-
induced thyrotoxicoses in an elderly patient without any classical 
presenting features but which was identified with ‘routine’ blood 
tests. Rae et al9 have stated that the diagnosis of thyroid disease 
in the elderly is even more dependent on laboratory results when 
compared to younger age groups. 
In the elderly, hypothyroidism is a more common reported 
complication of amiodarone medication than hyperthyroidism.2 
In a UK study carried out on 134 elderly patients taking long-
term amiodarone (80% aged > 70 years) it was found that 
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14% had developed hypothyroidism whilst 6% had features 
of thyrotoxicoses.10 Another UK study identified 15% of 
their sample with hypothyroidism (mean age 74 years) but 
hyperthyroidism was not noted.11 A local study on thyroid 
dysfunction in the elderly12 had noted that out of 20 patients on 
amiodarone medication, 40% had shown abnormalities in their 
thyroid function test results, of whom 2 patients (10%) had overt 
hypothyroidism, 5 (25%) had subclinical hypothyroidism and 1 
patient (5%) had subclinical hyperthyroidism. 
In view of the documented common complication of clinical 
and subclinical thyroid dysfunction coupled with a lack of 
classical symptoms and signs in the elderly, various authors have 
advised measuring thyroid function status on a regular basis on 
all patients on amiodarone. For example, the British National 
Formulary1 recommends that appropriate thyroid status blood 
tests are carried out, both at the start of the medication and 
at six month intervals thereafter, for as long as each patient 
remains on amiodarone. 
When overt thyroid dysfunction does occur in patients on 
amiodarone, various treatment options have been described 
including stopping the medication if the arrhythmia has 
subsided or switching to another anti-arrhythmic if the 
arrhythmia is still present or adding appropriate thyroid 
medication if amiodarone cannot be discontinued.2 On the 
other hand, no specific intervention is required for sub-clinical 
abnormalities but patients should be kept under review for 
as long as they remain on amiodarone in case overt thyroid 
dysfunction does occur.2 
This study was mainly carried out to evaluate whether elderly 
patients taking amiodarone were having their thyroid function 
monitored as recommended in the literature and to identify 
which thyroid function test abnormalities were being noted and 
what course of action was being followed. 
Methodology 
This study was carried out at two local institutions providing 
medical services for the elderly in Malta i.e. St Vincent de 
Paule Residence (SVPR), a long-stay chronic care facility and 
Zammit Clapp Hospital (ZCH), a short-stay assessment and 
rehabilitation unit. 
Subjects included (a) patients who were residents at SVPR 
during the time of the study and (b) consecutive admissions 
into ZCH. Data was collected over a 5 month period. Patients 
on amiodarone were identified from their prescription charts 
and their medical files examined to obtain the following 
information: 
1. The duration of treatment
2. The reason why the medication was started 
3. Where the decision was made to start the medication 
4. Whether thyroid function tests had been checked at: 
 a. the start of the medication, 
 b. every 6 months 
 c. or over the previous 12 months. 
5.  The results of the last documented thyroid function tests. 
6. Whether any patient was already taking, or was started 
on, thyroid medication for identified hypothyroidism or 
hyperthyroidism. 
7. The report of the last documented ECG. 
Results and data analysis
During the period of this study, 985 prescription charts 
were examined at SVPR and 349 at ZCH. 38 residents at SVPR 
were identified as taking amiodarone on a regular basis (3.9% 
of residents) and 31 patients at ZCH (8.9% of admitted patients) 
giving a total sample of 69 (5.2%) out of 1334 prescription charts 
examined. 
Figure 2: Site where medication commencedFigure 1: Time period on amiodarone
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69.6% of the total sample were females and 30.4% males. 
Their mean age was 82.3 years (range 68 – 94). 
The majority of patients in this sample (52.2%) had been 
taking amiodarone for between 1 to 5 years (Figure 1). The 
overall range varied from 7 days to 16 years. Out of the total 
sample, 30.4% had been taking the medication for up to a year 
whilst 65.2% had been taking the medication for more than a 
year (Figure 1). However, there were differences between the 
SVPR and ZCH samples as nearly two thirds of the ZCH sample 
had been on the medication for less than a year whilst nearly 
all the SVPR sample had been taking the medication for greater 
than one year (Table 1).
The majority of patients were started on amiodarone whilst 
under the care of physicians at St Luke’s Hospital, the local 
acute/general hospital (Figure 2), whilst the most common 
clinical indication to commence this medication (Figure 3) was 
sustained or paroxysmal atrial fibrillation (68.1%). 
Table 2 indicates whether thyroid function tests were 
checked at the start of the medication and every 6 months as 
recommended in the literature. For the majority the answer was 
no, as less than a third of subjects had their thyroid gland status 
checked at the start, whilst only 2 subjects had their thyroid 
function tests checked every 6 months. 
As can also be noted in Table 2, the study identified 47 
patients who had been on amiodarone for more than 6 months 
but who did not have their thyroid function status checked 
regularly. Data on this sample showed (Table 3) that 4 patients 
had never had any thyroid function tests carried out, 6 had only 
one result documented whilst 37 patients who had 2 or more 
thyroid function test results filed in their medical notes had a 
mean period of 26.2 months between their last two tests. 
Although the majority of subjects did not have their thyroid 
function status regularly measured within the recommended 
time frame, thyroid function tests had actually been carried out 
over the previous year for 52 subjects (75.4% of the total sample) 
an indication that doctors were aware that such monitoring 
should take place. On the other hand, 6 patients (8.7%) had 
Figure 3: Reason to commence amiodarone Figure 4: TSH levels
 SVPR  ZCH Total
 Sample Sample Sample
 n = 38 n = 31 n = 69
 
Up to 1 month 0 11 11
2 to 6 months 2  6  8
7 to 12 months 0  2  2
Number of subjects 2 9 2
taking medication   
for up to a year (5.%) (6.%) (0.4)%
> 1 year to 5 years 29 7 36
6 years to 10 years   5 0   5
11 years and over   2 2   4
   
Number of subjects 6 9 45
taking medication    
for more than a year (94.7%) (29.0%) (65.2%)
Unknown 0 3 3
SVPR – St Vincent de Paule Residence
ZCH   - Zammit Clapp Hospital
Table 1: Time period on amiodarone
Thyroid function  At start of Every 6 months
checked medication
Yes 27 (39.1%) 2 (2.9%)
No 33 (47.8%) 47 (68.1%)
Too early 
(on medication  Not relevant 18 (26.1%)
for less than 
6 months)   
Unknown 9 (13.1%) 2 (2.9%)
Total 69 (00%) 69 (00%)
Table 2: Thyroid function tests checked at start 
 and every 6 months 
Number of subjects
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never had their thyroid function tests checked at any stage, of 
which 2 had been on the medication for less than 6 months. 
Table 4 lists the results of the last recorded thyroid function 
tests per subject. These results are based either on tests carried 
out as part of the routine clinical work-up on patients or on blood 
tests that were requested for the purpose of this study when it 
was noted that no results for the previous year were available. 
Data on thyroid stimulation hormone (TSH) levels is mainly 
presented (Figure 4) as in the majority of cases this was the only 
test performed by the laboratory. Serum thyroxine levels (T4) 
were usually only measured automatically by the laboratory 
if TSH levels were above or below normal whilst none of the 
subjects had T3 levels measured even when the TSH level was 
noted to be low. 
In all, 18 patients (26.1%) had abnormal thyroid function 
tests, with the most common abnormality being a raised 
TSH level with a normal T4 level (Figure 5). However, an 
interpretation of these results has to keep in mind that a 
number of patients were already taking thyroxine at the time 
when the blood samples were taken. For example, one patient 
on thyroxine had normal thyroid function tests, indicating 
adequate treatment, whilst 4 of the patients with high TSH levels 
and normal T4 levels were also taking thyroxine medication, 
Figure 5: Thyroid function tests results Figure 6: Report of last recorded ECG
indicating the optimal dose had not as yet been achieved. 
Therefore, an examination of the whole picture, i.e. patients on 
thyroid medication and the results of thyroid function tests, can 
conclude that, in all, 19 patients (27.5% of the total sample) on 
amiodarone had thyroid gland dysfunction, of whom 8 (11.6%) 
were being treated for hypothyroidism, 9 (13.0%) had subclinical 
features of hypothyroidism and were not on treatment and 2 
(2.9%) had hyperthyroidism but were not receiving specific 
treatment. 
There was no evidence in any of the files that a patient had 
been taking thyroxine prior to being prescribed amiodarone nor 
were there any abnormal thyroid function tests documented 
in patients who had such measurements carried out prior to 
commencing amiodarone. The abnormal thyroid function tests 
detected in this study can therefore be attributed to an adverse 
effect of amiodarone. 
Discussion 
Although this study only identified a small percentage of 
patients on amiodarone, both at St Vincent de Paule Residence 
and at Zammit Clapp Hospital, it has shown that in a majority of 
Thyroid function checked Number of patients
Never 4 Mean period on amiodarone 
  40.5 months (range 36 – 44 months)
Once 6 Mean period on amiodarone 
  37.0 months (range 16 – 69 months)
Twice or more 37 Mean period between last 2 Thyroid Function Tests
  26.2 months (range 7 to 108 months)
Total 47
Table 3: Analysis of data on patients who had been on amiodarone for more than 6 months 
 but who did not have their thyroid function status checked every 6 months
Number of subjects
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cases, follow up procedures, as recommended in the literature, 
were not strictly adhered to. Thyroid function tests were not 
performed routinely, in a high percentage of cases, both at 
the start of the medication and on a regular six month basis. 
Similar findings have been reported in the literature. For 
example, McCulloch et al10 found that thyroid function tests were 
performed in 67% of their sample at the start of the medication 
and in only 30% of patients at the 6 and 12 month intervals. 
The possibility could be raised that patients might have 
had their thyroid function status checked elsewhere, such as in 
the community, by health centre doctors or specialists or even 
private family practitioners and therefore results would not 
be documented in the patient’s hospital file which formed the 
basis of this study. It was not possible to ascertain if the main 
hospital laboratory or private laboratories had any records 
of such monitoring in the community. However, most of the 
patients in the study sample (59 out of 69) were commenced 
on amiodarone by hospital based departments and the onus 
should be on doctors working in such departments to continue 
monitoring patients. This study has shown that such monitoring 
was not carried out on a recommended regular basis. 
Although this study was carried out on patients under the 
care of doctors working in the Department of Geriatric Medicine, 
most patients on this medication were ‘inherited’, as the decision 
to start amiodarone was mainly made whilst they were being 
managed by specialists working in the Department of Medicine 
at St Luke’s Hospital. Also, a number of patients had been on the 
medication for a considerable time before they required clinical 
input from the Department of Geriatric Medicine. No attempt 
was made in this study either to compare the two departments 
or to compare SVPR with ZCH as regards the recommended 
monitoring of patients. Suffice to say that both departments 
and both institutions need to ensure that thyroid function status 
is measured on a more regular basis. For example, 2 cases of 
clinical hypothyroidism and 1 of clinical hyperthyroidism were 
only identified because laboratory tests were requested for the 
purpose of this study. Doctors looking after such patients were 
informed about such abnormal findings and advised on what 
appropriate action to take. 
This study has also confirmed that locally, thyroid function 
is commonly impaired in elderly patients on amiodarone, 
thereby emphasizing even further the need for regular 
monitoring. Hypothyroidism, both clinical and subclinical, 
was a more common abnormality affecting 24.6% of patients in 
this sample. On the other hand, only 2.9% showed features of 
hyperthyroidism. In all, 27.5% of patients had thyroid function 
abnormalities. Although this percentage is not as high as 
previously quoted, when 40% of patients were found to have 
abnormalities of thyroid function tests12, it is still more than the 
incidence rate of 2% to 24% as reported in the literature.4 As 
already stated, none of the patients in this study had documented 
thyroid dysfunction before starting amiodarone. Therefore, the 
abnormalities noted can be attributed to the medication. 
It was also interesting to note from this study that over 
half of the subjects had documented evidence that the 
electrocardiogram abnormality which had precipitated the start 
of the medication had resolved (Figure 6). In other words, these 
patients were still kept on amiodarone even though the original 
clinical indication had abated. For example, 4 patients had 
been on amiodarone for more that 10 years, of whom 3 showed 
persistently normal electrocardiogram recordings. Throughout 
the course of this study, amiodarone was discontinued in only 
one patient because a marked bradycardia was noted. Even those 
patients who required thyroxine were kept on amiodarone. As 
already discussed in the introduction, an accepted alternative 
treatment could have been to stop amiodarone and see if the 
thyroid function corrects itself. For example in a study by Hyatt 
et al11, which documented clinical hypothyroidism in 9 patients, 
the thyroid dysfunction reverted to normal in 5 patients by 
simply withdrawing the medication, 2 patients needed to remain 
on amiodarone and were commenced on thyroxine, whilst the 
other 2 patients still required thyroxine even though amiodarone 
was discontinued. 
Thyroid function results Number of patients  Mean and range of Mean and range of     Number of patients on
 and  % of sample             TSH levels (μU/L) T4 levels (pmol/L) thyroid medication
high TSH low T4 3 (4.4%) 46.2 (41.7 -49.0) 4.5 (2.9-5.4) 3 
high TSH  normal T4 13 (18.8%) 7.6 (4.3-13.8) 17 (12.0-24.0) 4
low TSH high T4 2 (2.9%) 0.16 (0.1+0.23) 25.8 (25.0+26.5) 0
low TSH normal T4 0   0
normal TSH 47 (68.1%) 1.9 (0.4-4.0)  1
unknown 4 (5.8%)   0
Total 69 (00%)   8
Normal range: TSH=0.4 – 4.0 µU/l    T4=10.3 – 24.45 pmol/l
Table 4: Results of thyroid function tests 
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Conclusion and recommendations 
Thyroid dsysfunction is a common side-effect of amiodarone 
medication. This study has shown that patients on amiodarone 
need to be followed up more carefully whilst the regular 
measurement of thyroid function tests, needs to be adhered 
to in a stricter manner. Furthermore, in a number of cases, 
amiodarone may no longer be required and any regular follow-
up should pose the question whether the medication can and 
should be discontinued. Certainly, stopping the medication is 
one management alternative which should be considered when 
thyroid dysfunction is noted. 
The findings of this study have been formally presented to 
doctors working in the Department of Geriatric Medicine in an 
attempt to optimize patient monitoring. However, omissions 
by other clinical departments prescribing this medication were 
also identified by this study. It is hoped that this publication 
will serve to remind all doctors about the recommended clinical 
guidelines for patients prescribed amiodarone. These include 
the measurement of thyroid function status at the start of the 
medication and at regular 6 monthly intervals even if previous 
results are normal, with the added recommendation that if 
thyroid dysfunction is noted, amiodarone is either stopped 
(especially if the arrhythmia has subsided) or appropriate 
thyroid medication added to the patient’s regime. 
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